Originally shared by Barb Kueber
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470840/ "The literature cited in this review provides incontrovertible evidence that cannabinoids are immunosuppressive. The discovery of a cannabinoid receptor, CB2, primarily expressed on cells of the immune system and not neurons, with strong immunosuppressive effects on T-cells, opens the possibility of developing drugs that target this receptor in conditions where the immune system is over-active, as in autoimmune diseases and in graft rejection. Such drugs are expected to be without psychoactive effects. These studies also give credence to medicinal uses of Δ9-THC that relate to dampening immune function. This review has focused on T-cells, but Δ9-THC as well as the CB2 selective agonists, all have suppressive effects on B-cells, monocyte/macrophages, and dendritic cells. T-cells play a major role as effectors in a variety of autoimmune conditions, so demonstration of their down-regulation by cannanbinoids is of special importance in terms of possible therapeutic value of this class of compounds. Further, the observations by several laboratories that the endogenous cannabinoid, anandamide, which binds to both CB1 and CB2 receptors, is also immunosuppressive, and that genetic ablation of the CB2 receptor activates the immune system, strongly indicates that the cannabinoid system is important in immune homeostatis."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470840/
No comments:
Post a Comment